Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland

Daniel Tobias Michaeli,Mackenzie Mills,Panos Kanavos
DOI: https://doi.org/10.1007/s40258-022-00737-w
2022-07-14
Applied Health Economics and Health Policy
Abstract:Oncology drugs are often approved for multiple indications, for which their clinical benefit varies. Aligning a single price to this differing value remains a challenge. This study examines the clinical and economic value, price, and reimbursement of multi-indication cancer drugs across seven countries, representing different approaches to value assessment, pricing, and coverage decisions: the USA, Germany, France, England, Canada, Australia, and Scotland.
health care sciences & services,health policy & services,economics
What problem does this paper attempt to address?